| abstract |
The present invention relates to the use of derivatives of salicylic acid for the treatment of diseases or conditions linked to GO and/or PRODH2 enzyme activity, in particular diseases linked to an excess of oxalate, and for the treatment of patients with renal insufficiency (uremia or azotaemia) receiving haemodialysis or peritoneal dialysis, in particular patients treated with ascorbic acid (vitamin C), which is metabolised to oxalate, or patients with fibromyalgia and vulvar pain. |